Vertex gets reimbursement deal for Orkambi in Sweden

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said June 18 it agreed to a long-term access agreement for cystic fibrosis drug Orkambi lumacaftor/ivacaftor with Swedish authorities.

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE